Kaijin Wu

Kaijin Wu

Auto-generated profile, based on publicly available information

Kaijin Wu

University of Southern California 3 Division of Hematology, Health Sciences Campus Los Angeles, California

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
Steffan T. NawrockiSteffan T. Nawrocki
Steffan T. Nawrocki
JOJulian Olea
Julian Olea
CCClaudia S Villa Celi
Claudia S Villa Celi
HDHoma Dadrastoussi
Homa Dadrastoussi
KWKaijin Wu
Kaijin Wu
KKKevin Kelly
Kevin Kelly
Purpose: Our preclinical studies showed that the oncolytic reovirus formulation pelareorep (PELA) has significant immunomodulatory anti-myeloma activity. We conducted an investigator-initiated clinical trial to evaluate PELA in combination with dexamethasone (Dex) and bortezomib (BZ) and define the tumor immune microenvironment (TiME) in patients with multiple myeloma treated with this regimen. Patients and Methods: Patients with relapsed/refractory multiple myeloma (n = 14) were enrolled in a phase Ib clinical trial (ClinicalTrials.gov: NCT02514382) of three escalating PELA doses administered on Days 1, 2, 8, 9, 15, and 16. Patients received 40 mg Dex and 1.5 mg/m2 BZ on Days 1, 8, and 15. Cycles were repeated every 28 days. Pre- and posttreatment bone marrow specimens (IHC, n = 9; imaging mass cytometry, n = 6) and peripheral blood samples were collected for analysis (flow cytometry, n = 5; T-cell receptor clonality, n = 7; cytokine assay, n = 7). Results: PELA/BZ/Dex was well-tolerated in all patients. Treatment-emergent toxicities were transient, and no dose-limiting toxicities occurred. Six (55%) of 11 response-evaluable patients showed decreased paraprotein. Treatment increased T and natural killer cell activation, inflammatory cytokine release, and programmed death-ligand 1 expression in bone marrow. Compared with nonresponders, responders had higher reovirus protein levels, increased cytotoxic T-cell infiltration posttreatment, cytotoxic T cells in significantly closer proximity to multiple myeloma cells, and larger populations of a novel immune-primed multiple myeloma phenotype (CD138+ IDO1+HLA-ABCHigh), indicating immunomodulation. Conclusions: PELA/BZ/Dex is well-tolerated and associated with anti–multiple myeloma activity in a subset of responding patients, characterized by immune reprogramming and TiME changes, warranting further investigation of PELA as an immunomodulator.

1 June 2026 in Cancer Research Communications
Verified
Journal Article
Open access
Steffan T. NawrockiSteffan T. Nawrocki
Steffan T. Nawrocki
NWNing Wang
Ning Wang
CEClaudia M. Espitia
Claudia M. Espitia
HWHarley Wu
Harley Wu
CCClaudia S Villa Celi
Claudia S Villa Celi
KKKevin Kelly
Kevin Kelly
Acute myeloid leukemia (AML) remains defined by therapeutic resistance, adverse genetic heterogeneity, and poor long-term survival, underscoring the need for mechanistically informed regimens that exploit core stress-adaptation liabilities. Polo-like kinase 1 (PLK1) is a central regulator of replication recovery and mitotic progression, yet direct PLK1 inhibitors have been limited by tolerability and incomplete target suppression. Here, we define a clinically actionable strategy that functionally targets PLK1 by combining inhibition of the AAA+ ATPase p97/valosin-containing protein with the hypomethylating agent decitabine (DAC). Using AML cell lines, primary patient specimens, and an orthotopic in vivo model, we show that the clinically relevant p97 inhibitor CB-5339 induces proteotoxic and replication stress, activates the unfolded protein response, and triggers apoptosis. Formal synergy analyses demonstrate that CB-5339 and DAC cooperate across molecular subtypes, including FLT3-ITD+, KMT2A-rearranged, and TP53-mutant AML, to reduce cell viability at pharmacologically relevant concentrations. Transcriptomic, biochemical, and genetic studies identify synergistic suppression of PLK1 as a central consequence of combination treatment, converting stress-dependent PLK1 reliance into a therapeutic vulnerability. Consistent with this mechanism, PLK1 knockdown phenocopies the antileukemic effects of the combination and enhances sensitivity to both agents. In vivo, CB-5339/DAC is well tolerated, significantly prolongs survival, reduces leukemic burden, and suppresses PLK1 in bone marrow blasts. Together, these data establish p97 inhibition as a rational means to exploit replication and proteotoxic stress in AML and provide strong rationale for clinical evaluation of CB-5339 plus DAC in high-risk disease. Significance: This study defines a clinically actionable strategy to overcome therapeutic resistance in AML by functionally suppressing PLK1 through combined p97 inhibition and hypomethylating therapy. By exploiting convergent proteotoxic and replication stress, the regimen produces robust, well-tolerated antileukemic activity across high-risk genetic subtypes, supporting near-term clinical evaluation.

26 June 2026
Verified
Other
Open access
Steffan T. NawrockiSteffan T. Nawrocki
Steffan T. Nawrocki
NWNing Wang
Ning Wang
CEClaudia M. Espitia
Claudia M. Espitia
HWHarley Wu
Harley Wu
CCClaudia S Villa Celi
Claudia S Villa Celi
KKKevin Kelly
Kevin Kelly
Figure S5. Time course cell viability analysis following treatment with CB-5339, DAC, and the combination.

26 June 2026
Verified
Other
Open access
Steffan T. NawrockiSteffan T. Nawrocki
Steffan T. Nawrocki
NWNing Wang
Ning Wang
CEClaudia M. Espitia
Claudia M. Espitia
HWHarley Wu
Harley Wu
CCClaudia S Villa Celi
Claudia S Villa Celi
KKKevin Kelly
Kevin Kelly
Effects of the CB-5339/DAC combination on the transcriptomic landscape. A, MOLM-13 and MV-4-11 cells were treated with 500 or 1,000 nmol/L CB-5339 for 6 or 12 hours. RNA sequencing was performed, and the numbers of upregulated and downregulated genes were quantified for each experimental condition. B–E, Ingenuity Pathway Analysis of RNA sequencing results for (B and C) MOLM-13 and (D and E) MV4-11. Cell processes and disease-related and functional pathways are sorted by absolute Z-score.

26 June 2026
Verified
Other
Open access
Steffan T. NawrockiSteffan T. Nawrocki
Steffan T. Nawrocki
NWNing Wang
Ning Wang
CEClaudia M. Espitia
Claudia M. Espitia
HWHarley Wu
Harley Wu
CCClaudia S Villa Celi
Claudia S Villa Celi
KKKevin Kelly
Kevin Kelly
CB-5339 in combination with DAC prolongs survival and is well tolerated in an orthotopic AML xenograft model. A, The CB-5339/DAC combination significantly increases overall survival. A disseminated mouse model of AML was generated by injecting MV4-11 cells into the tail veins of NOG mice. Mice were treated with vehicle control, 50 mg/kg CB-5339 daily (oral), 2.5 mg/kg DAC twice weekly (intraperitoneally), or both drugs for the duration of the study. Overall survival for each group was determined by Kaplan–Meier analysis. N = 10 ± SD; * indicates a significant difference from control and single-agent groups, P < 0.005. Median survival values are as follows: vehicle = day 14, CB-5339 = day 19, DAC = day 18, and CB-5339 + DAC = day 22. B, The CB-5339/DAC combination is well tolerated. Mouse weight is shown for all treatment groups. N = 10 ± SD. C, Administration of the CB-5339/DAC combination diminishes CD33+ blasts and PLK1 levels in vivo. Bone marrow specimens were collected from mice in all experimental groups and subjected to IHC analysis to quantify PLK1 and CD33 (leukemia cell marker) levels. Scale bar, 50 μm. D, Quantification of IHC analyses. The number of CD33+ cells were counted in five random fields. For PLK1, signal intensity was quantified using ImageJ software. N = 5 ± SD; * indicates a significant difference from control and single-agent groups, P < 0.005. E, Schematic illustration of the pharmacodynamic synergy of the CB-5339/DAC combination.

26 June 2026
Verified
Other
Open access
Steffan T. NawrockiSteffan T. Nawrocki
Steffan T. Nawrocki
NWNing Wang
Ning Wang
CEClaudia M. Espitia
Claudia M. Espitia
HWHarley Wu
Harley Wu
CCClaudia S Villa Celi
Claudia S Villa Celi
KKKevin Kelly
Kevin Kelly
Figure S6. Quantification of PLK1 immunoblotting from (A) Figure 4C and (B) 4D. Band intensity was measured using Image J software.